31924-81-9

Basic information

• Product Name: 3-AMINO-5-METHYL-4-PHENYLPYRAZOLE
• Synonyms: 3-AMINO-5-METHYL-4-PHENYLPYRAZOLE;5-METHYL-4-PHENYL-1H-PYRAZOLE-3-YLAMINE
• CAS NO: 31924-81-9
• Molecular Formula: C₁₀H₁₁N₃
• Molecular Weight: 173.21
• Mol File: 31924-81-9.mol

Chemical Properties

• Melting Point: 140-142 °C
• Boiling Point: 368.5 °C at 760 mmHg
• Flash Point: 204.3 °C
• Appearance: /
• Density: 1.196 g/cm³
• PKA: 15.78±0.50(Predicted)
• CAS DataBase Reference: 3-AMINO-5-METHYL-4-PHENYLPYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-5-METHYL-4-PHENYLPYRAZOLE(31924-81-9)
• EPA Substance Registry System: 3-AMINO-5-METHYL-4-PHENYLPYRAZOLE(31924-81-9)

Safety Data

• Hazardous Substances Data: 31924-81-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-5-METHYL-4-PHENYLPYRAZOLE is used as a therapeutic agent for the diagnosis and treatment of cardiovascular diseases and conditions. Its application in this field is due to its ability to target and modulate specific biological pathways involved in the development and progression of these diseases.
Used in Cardiovascular Applications:
In the field of cardiology, 3-AMINO-5-METHYL-4-PHENYLPYRAZOLE is used as a diagnostic tool to identify and monitor cardiovascular diseases. Its application in this area is based on its ability to interact with specific molecular targets, allowing for the detection and assessment of the severity of these conditions.
Additionally, 3-AMINO-5-METHYL-4-PHENYLPYRAZOLE is used as a treatment option for various cardiovascular diseases, including hypertension, atherosclerosis, and heart failure. Its application in these cases is due to its potential to improve blood flow, reduce inflammation, and protect the heart from damage caused by these conditions.

Upstream product

• 140-29-4 phenylacetonitrile 
• 4468-48-8 1-phenyl-1-cyanopropan-2-one 
• 109013-33-4 5-Amino-3-methyl-4-phenyl-1H-pyrazol-1-carbonsaeure-methylester 
• 537-47-3 4-phenyl-semicarbazide 
• 109013-19-6 5-Amino-3-methyl-N,4-diphenyl-1H-pyrazol-1-carboxamid 

Downstream Products

• 375835-42-0 2-methyl-3-phenyl-5-(2''-thienyl)-7-trifluoromethylpyrazolo[1,5-a]pyrimidine 
• 1236182-45-8 C₂₃H₁₈N₄S 
• 130159-67-0 3,5-Diphenyl-2-methylpyrazolo<1,5-a>pyrimidine 
• 130159-70-5 2-Methyl-3,7-diphenyl-pyrazolo[1,5-a]pyrimidine 
• 79442-64-1 7-Methyl-4,8-diphenyl-pyrazolo[5,1-c][1,2,4]triazine 
• 79441-95-5 4,7-Dimethyl-8-phenyl-pyrazolo[5,1-c][1,2,4]triazine 
• 91120-64-8 2,3,4,5-Tetraphenyl-2,4-cyclopentadien-1-on-(3-methyl-4-phenyl-1H-pyrazol-5-yl)hydrazon 
• 91120-44-4 6-Methyl-7-phenylspiro<3H-pyrazolo<5,1-c>-1,2,4-triazol-3,9'-<9H>-thioxanthen>-S,S-dioxid 
• 91120-41-1 10,11-Dihydro-6'-methyl-7'-phenylspiro<5H-dibenzocyclohepten-5,3'-<3H>pyrazolo<5,1-c><1,2,4>triazol> 
• 91120-42-2 6-Methyl-7-phenylspiro<3H-pyrazolo<5,1-c>-1,2,4-triazol-3,9'-<9H>xanthen> 
• 91120-43-3 6'-Methyl-7'-phenylspiropyrazolo<5,1-c><1,2,4>triazol>-10-on 
• 91120-46-6 3,3,6-Trimethyl-7-phenyl-3H-pyrazolo<5,1-c>-1,2,4-triazol 
• 72403-82-8 6'-Methyl-2,3,4,5,7'-pentaphenylspiro<2,4-cyclopentadien-1,3'-<3H>-pyrazolo<5,1-c><1,2,4>triazol> 
• 72403-81-7 6'-Methyl-7'-phenylspiro<9H-fluoren-9,3'-<3H>pyrazolo<5,1-c><1,2,4>triazol> 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZIN-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE ANALOGS AS INHIBITORS OF KRAS

In one aspect, the disclosure relates to compounds useful as inhibitors of mutant KRAS proteins, methods of making the same, pharmaceutical compositions comprising the same, and methods of treating cancers associated with mutated forms of KRAS using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF

Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.

N -Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK

NF-κB-inducing kinase (NIK), an oncogenic drug target that is associated with various cancers, is a central signalling component of the non-canonical pathway. A blind screening process, which established that amino pyrazole related scaffolds have an effect on IKKbeta, led to a hit-to-lead optimization process that identified the aminopyrazole 3a as a low μM selective NIK inhibitor. Compound 3a effectively inhibited the NIK-dependent activation of the NF-κB pathway in tumour cells, confirming its selective inhibitory profile.

Structure and tautomerism of 4-substituted 3(5)-aminopyrazoles in solution and in the solid state: NMR study and Ab initio calculations

Annular tautomerism of 3(5)-aminopyrazoles containing a cyano, thiocyanato, or aryl substituent in the 4-position has been studied by 1H and 13C NMR in solution, cross-polarization and magic-angle spinning 13C NMR in the s

Synthesis and biological evaluation of 7-trifluoromethylpyrazolo[1,5-a]pyrimidines as anti-inflammatory and antimicrobial agents

A series of 2-H/methyl-3-phenyl-5-alkyl/aryl/heteroaryl-7-trifluoromethylpyrazolo[1,5-a]pyrimidines (4a-l) were synthesized by refluxing 3(5)-amino-4-phenyl-5(3)-H/methyl-1H-pyrazoles (1-2) with trifluoromethyl-?2-diketones (3a-f) in ethanol for 6 h. The

Study of regioselectivity of reactions between 3(5)-aminopyrazoles and 2-acetylcycloalkanones

Regioselectivity was examined of reactions between nine 3(5)-aminopyrazoles and 2-acetylcyclopentanone and 2-acetylcyclohexanone under various conditions. A series of cyclopenta[e]pyrazolo-[1,5-a]pyrimidines was obtained. The highest regioselectivity of the reaction was observed in alcohol at 20°C in the presence of a catalytic quantity of trifl uoroacetic acid. The regiostructure of compounds was established by 1H and 13C NMR spectroscopy. Pleiades Publishing, Ltd., 2012.

Reactions with Diazoazoles, VIII. - Syntheses of Azolo-1,2,3,5-tetrazin-4(3H)-ones

Azolo-1,2,3,5-tetrazin-4(3H)-ones 4 and 5 are formed by cycloaddition reactions of α-diazoazoles 2 with aryl or alkyl isocyanates 3a-p, respectively, as well as with diisocyanates 3q,r (Method A).Alternative syntheses for 4 are presented by diazoti